
David A Santos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1262375/publications.pdf Version: 2024-02-01



DAVID A SANTOS

#	Article	IF	CITATIONS
1	Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 48-56.	10.7	189
2	B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clinical Cancer Research, 2017, 23, 4212-4223.	7.0	49
3	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances, 2020, 4, 1038-1050.	5.2	43
4	Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nature Communications, 2021, 12, 2877.	12.8	35
5	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. Journal of Clinical Oncology, 2022, 40, 202-212.	1.6	34
6	lbrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (â‰ ø 5 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncology, The, 2022, 23, 406-415.	10.7	22
7	Laparoscopic common bile duct exploration versus endoscopic retrograde cholangiopancreatography for choledocholithiasis found at time of laparoscopic cholecystectomy: Analysis of a large integrated health care system database. American Journal of Surgery, 2017, 214, 1075-1079.	1.8	18
8	The current state of robotic retromuscular repairs—a qualitative review of the literature. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 456-466.	2.4	18
9	Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤5 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial. Blood, 2019, 134, 3987-3987.	1.4	12
10	Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65) Tj ETC 3988-3988.	Qq0 0 0 rgE 1.4	3T /Overlock 1 11
11	Appendicitis in Cancer Patients is often Observed and Can Represent Appendiceal Malignancy. American Surgeon, 2016, 82, 1028-1032.	0.8	10
12	Management of surgical challenges in actively treated cancer patients. Current Problems in Surgery, 2017, 54, 612-654.	1.1	10
13	Predictors of Failed Transcystic Laparoscopic Common Bile Duct Exploration: Analysis of Multicenter Integrated Health System Database. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2019, 29, 360-365.	1.0	10
14	Custom 3D-printed Titanium Implant for Reconstruction of a Composite Chest and Abdominal Wall Defect. Plastic and Reconstructive Surgery - Global Open, 2021, 9, e3885.	0.6	6
15	Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial. Blood, 2020, 136, 35-36.	1.4	4
16	Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial. Blood, 2020, 136, 41-42.	1.4	3
17	Use of non-operative treatment and interval cholecystectomy for cholecystitis in patients with cancer. Trauma Surgery and Acute Care Open, 2020, 5, e000439.	1.6	2
18	Chemotherapy and Abdominal Wall Closure Technique Increase the Probability of Postoperative Ventral Incisional Hernia in Patients With Colon Cancer. American Surgeon, 2023, 89, 98-107.	0.8	2

#	Article	IF	CITATIONS
19	Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq. Blood, 2019, 134, 5217-5217.	1.4	Ο
20	Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma. Blood, 2020, 136, 33-34.	1.4	0